The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Sandra J. Lee
No relevant relationships to disclose
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb
Uma N. M. Rao
No relevant relationships to disclose
Lisa H. Butterfield
No relevant relationships to disclose
Ahmad A. Tarhini
Consultant or Advisory Role - AstraZeneca; Genentech; Merck; Prometheus
Research Funding - Amgen; Bristol-Myers Squibb; ecog/NIH; Merck; Prometheus
Philip D. Leming
No relevant relationships to disclose
Igor Puzanov
No relevant relationships to disclose
John M. Kirkwood
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis; Vical
Research Funding - Prometheus